Interestingly, isocitrate dehydrogenase (IDH) 1 and 2 mutation status may also affect the response to BCL-2 inhibition, as IDH1 and IDH2 mutant primary human AML cells have been demonstrated to be more sensitive to venetoclax treatment than those with wild type IDH 1/2 (47). This evidence concerns the gene IDH1 and acute myeloid leukemia.